Pfizer Inc
Jim Cramer’s top 10 things to watch in the stock market Friday
My top 10 things to watch Friday, Feb. 20 1. Blue Owl Capital’s loan sales, part of a plan to return capital to investors, has observers bringing out “canary in the coal mine” warnings again. While many private credit loans seem mismarked, this situation doesn’t appear tragic in nature. 2. Stock futures were lower after […]
Read More
Walmart earnings, Fed meeting minutes, Zuckerberg’s testimony and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Thursday. My spin class soundtrack of mainly Kesha’s music last night was more evidence that the 2016 aesthetic is back. Stock futures are lower this morning. The three major indexes are coming off a winning session. Here are five key things […]
Read More
FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal
A researcher works in the lab at the Moderna headquarters in Cambridge, Massachusetts, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images Moderna said on Wednesday the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing the agency’s earlier decision to refuse to accept the application in a move […]
Read More
FDA chief Marty Makary says ‘everything should be over the counter’ unless drug is unsafe or addictive
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter” unless a drug is unsafe, addictive or requires monitoring – doubling down on a push that some in the pharmaceutical industry have questioned. In an interview Wednesday in Washington, D.C., Makary said the FDA aims to make […]
Read More
Prices, pipelines and patent cliffs: Inside pharma’s big reset
This earnings season, Europe’s biggest pharma companies posted results ranging from 7% beats to 3% misses — but no one really cared. Instead, drugmakers looked ahead, with 2026 shaping up to be a defining year following a dramatic 2025, and one where the impact from last year’s developments is set to crystallize. “2025 was about […]
Read More
Stocks making the biggest moves midday: Novo Nordisk, Palantir, AES, Rocket and more
Check out the companies making headlines before the bell: Novo Nordisk — The maker of obesity drug Wegovy’s U.S. stock fell about 13% after unexpectedly warning that fiscal 2026 sales will be hurt by lower drug prices in the U.S. even as it anticipates more patients will use its popular GLP-1 drug. Novo Nordisk said […]
Read More
The xAI-SpaceX merger, Palantir earnings, China’s frowning horses and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Tuesday. I did my workout studio’s Hyrox-themed class yesterday, which not only left me sore but also with a better understanding of what all the hype in the fitness business is about. S&P 500 futures ticked higher this morning. The stock […]
Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Smith Collection | Archive Photos | Getty Images Pfizer on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in […]
Read More
S&P 500 futures climb after index starts February trading on a winning note: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) on Jan. 28, 2026 in New York City. Spencer Platt | Getty Images Futures linked to the S&P 500 rose on Tuesday after U.S. equities posted a strong start to the new trading month. S&P 500 futures added 0.1%, while Nasdaq 100 futures […]
Read More
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more
Check out the companies making headlines before the bell: Palantir — The stock jumped 11% following the AI-powered software provider’s fourth-quarter earnings beat . Palantir reported adjusted earnings of 25 cents per share, versus the 23 cents expected from analysts polled by LSEG. Revenue was $1.41 billion, topping the $1.33 billion consensus estimate. Merck — […]
Read More